Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | CASP1 | P29466 | 1/20 | 0.51 |
| ▸ | CASP7 | P55210 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | TERT | O14746 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.43 |
| ▸ | TOP1 | P11387 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | MIF | P14174 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | UGCG | Q16739 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL768807 | 0.83 | MAPT (0.55) | MAPTKDM4ECASP1CASP7HSD17B10 | |
| SCHEMBL1181324 | 0.80 | MAPT (0.46) | MAPTKDM4ECASP1CASP7HSD17B10 | |
| SCHEMBL21807581 | 0.78 | PARP1 (0.46) | MAPTKDM4ECASP1CASP7HSD17B10 | |
| SCHEMBL1508794 | 0.78 | PARP1 (0.46) | MAPTKDM4ECASP1CASP7HSD17B10 | |
| SCHEMBL28330841 | 0.77 | KDM4E (0.51) | MAPTKDM4ECASP1CASP7HSD17B10 | |
| SCHEMBL14735454 | 0.77 | KDM4E (0.50) | MAPTKDM4ECASP1CASP7HSD17B10 | |
| SCHEMBL14735038 | 0.76 | PSMB5 (0.62) | MAPTKDM4ECASP1CASP7HSD17B10 | |
| SCHEMBL14735412 | 0.76 | KDM4E (0.49) | MAPTKDM4ECASP1CASP7HSD17B10 | |
| SCHEMBL10157261 | 0.76 | KDM4E (0.49) | MAPTKDM4ECASP1CASP7HSD17B10 | |
| SCHEMBL12178135 | 0.76 | PARP1 (0.54) | MAPTKDM4ECASP1CASP7HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160332016-A1 | Fire Extinguishing Composition Comprising Aldoketones Compound | NANO FIRE, LLC | 2016-11-17 | — | — | US | claimed |
| US-20250122213-A1 | OPIOID RECEPTOR MODULATORS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2025-04-17 | — | — | US | disclosed |
| US-12195478-B2 | Opioid receptor modulators | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2025-01-14 | — | — | US | disclosed |
| EP-4487913-A2 | OPIOID RECEPTOR MODULATORS | The Trustees Of Columbia University In The City Of New York (US) | 2025-01-08 | — | — | EP | disclosed |
| EP-3224261-B1 | OPIOID RECEPTOR MODULATORS | UNIV COLUMBIA (US) | 2024-09-18 | — | — | EP | disclosed |
| US-11840541-B2 | Opioid receptor modulators | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-12-12 | — | — | US | disclosed |
| US-11840541-B2 | Opioid receptor modulators | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-12-12 | — | — | US | disclosed |
| US-11840541-B2 | Opioid receptor modulators | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-12-12 | — | — | US | disclosed |
| EP-2735562-B2 | Estrogen receptor modulators and uses thereof | SERAGON PHARMACEUTICALS INC (US) | 2023-11-15 | — | — | EP | disclosed |
| CN-114507202-B | Phellinin compound and preparation method and application thereof | 海南大学 | 2023-10-03 | — | — | CN | disclosed |
| US-4868199-A | ENZYME INHIBITORS, ANTIALLERGEN, ASTHMA, CARDIOVASCULAR, ANTIINFLAMMATORY | WARNER-LAMBERT COMPANY (US) | 1989-09-19 | — | — | US | disclosed |
| US-4868205-A | ANTIALLERGENS, ANTIINFLAMMATORY, CARDIOVASCULAR DISORDERS | WARNER-LAMBERT COMPANY (US) | 1989-09-19 | — | — | US | disclosed |
| US-4868200-A | LEUKOTRIENES, LIPOXYGENASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1989-09-19 | — | — | US | disclosed |
| US-4868195-A | ENZYME INHIBITORS, ANTIALLERGEN, ASTHMA, CARDIOVASCULAR, ANTIINFLAMMATORY | WARNER-LAMBERT COMPANY (US) | 1989-09-19 | — | — | US | disclosed |
| US-4761424-A | Enolamides, pharmaceutical compositions and methods for treating inflammation | WARNER-LAMBERT COMPANY (US) | 1988-08-02 | — | — | US | disclosed |
| EP-0221345-A1 | Novel enolamides, process for their manufacture and pharmaceutical compositions thereof with an activity as modulators of the arachidonic acid cascade | WARNER-LAMBERT COMPANY (US) | 1987-05-13 | — | — | EP | disclosed |
| EP-0009780-B1 | OCTAHYDRO-1H-BENZO(4,5)FURO(3,2-E)ISOQUINOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1982-02-24 | — | — | EP | disclosed |
| US-4260761-A | Intermediates for the preparation of octahydro-1H-benzo[4,5]furo[3,2,-e]-isoquinoline analgesic and narcotic antagonistic compounds | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1981-04-07 | — | — | US | disclosed |
| US-4243668-A | Octahydro-1H-benzo[4,5]furo[3,2-e]-isoquinoline analgesic and narcotic antagonistic compounds | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1981-01-06 | — | — | US | disclosed |
| EP-0009780-A2 | Octahydro-1H-benzo(4,5)furo(3,2-e)isoquinoline derivatives, process for their preparation and pharmaceutical compositions containing them | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1980-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12195478-B2 | Opioid receptor modulators | OPRM1, OPRL1, OPRD1 | MAPT 3739/4885KDM4E 1372/4885CASP1 4679/4885 |
| US-20250122213-A1 | OPIOID RECEPTOR MODULATORS | OPRM1, OPRL1, OPRD1 | MAPT 3739/4885KDM4E 1372/4885CASP1 4679/4885 |
| US-11840541-B2 | Opioid receptor modulators | OPRM1, OPRL1, OPRD1 | MAPT 4252/4885KDM4E 1197/4885CASP1 4796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.